Diabetes Mellitus & Its Complications - Concept Map
Diabetes Mellitus: A Metabolic Disorder Affecting Glucose Regulation
Related concepts
Pathophysiology & Classification
Sub concepts
- Type 1 DM (Autoimmune Beta Cell Destruction)
- Type 2 DM (Insulin Resistance + Relative Deficiency)
- Gestational DM (Pregnancy-Related)
- Glucose Metabolism Dysfunction
- Hyperglycemia as Central Problem
Relationship to central
Defines the underlying mechanism and types of diabetes
Diagnostic & Monitoring Values
Sub concepts
- Fasting Plasma Glucose (≥126 mg/dL = DM)
- Random Plasma Glucose (≥200 mg/dL with symptoms)
- HbA1c (≥6.5% diagnostic; <7% treatment target)
- Oral Glucose Tolerance Test (2-hr ≥200 mg/dL)
- Classic Manifestations (3 Ps: Polyuria, Polydipsia, Polyphagia)
Relationship to central
Critical for identifying and assessing diabetes severity
Insulin Pharmacology & Management
Sub concepts
- Rapid-Acting Insulins (Lispro, Aspart, Glulisine)
- Short-Acting Insulin (Regular)
- Intermediate-Acting Insulin (NPH)
- Long-Acting/Basal Insulins (Glargine, Detemir)
- Insulin Administration & Injection Techniques
- Mixing Insulins (Clear before Cloudy Rule)
- Storage & Site Rotation to Prevent Lipohypertrophy
Relationship to central
Primary therapeutic agent, especially for Type 1; onset-peak-duration determines hypoglycemia risk
Oral & Non-Insulin Agents
Sub concepts
- Biguanides (Metformin)
- Sulfonylureas (Glipizide, Glyburide, Glimepiride)
- Meglitinides (Repaglinide, Nateglinide)
- Thiazolidinediones (Pioglitazone)
- DPP-4 Inhibitors (Sitagliptin)
- SGLT2 Inhibitors (Empagliflozin, Dapagliflozin)
- GLP-1 Receptor Agonists (Liraglutide, Semaglutide, Exenatide)
Relationship to central
Alternative/adjunctive pharmacotherapy for Type 2 DM management
Acute Complications
Sub concepts
- Hypoglycemia (Blood Glucose <70 mg/dL)
- Diabetic Ketoacidosis (DKA)
- Hyperglycemic Hyperosmolar Nonketotic Syndrome (HHNS/HHS)
- Pathophysiology of Each Emergency
- Clinical Manifestations & Diagnosis
- Emergency Management & Nursing Interventions
- Potassium Monitoring & Replacement Protocols
Relationship to central
Life-threatening emergencies requiring immediate intervention
Chronic (Long-Term) Complications
Sub concepts
- Microvascular Complications (Retinopathy, Nephropathy, Neuropathy)
- Macrovascular Complications (Coronary Artery Disease, Stroke, PVD)
- Foot Complications & Amputation Risk
- Diabetic Retinopathy & Blindness Prevention
- Diabetic Nephropathy & Renal Protection
- Diabetic Neuropathy (Peripheral & Autonomic)
- Cardiovascular Disease as Leading Cause of Death
Relationship to central
Preventable outcomes of prolonged hyperglycemia; require ongoing patient education
Patient Education & Self-Management
Sub concepts
- Glucose Monitoring & Self-Monitoring Blood Glucose (SMBG)
- Carbohydrate-Consistent Diet & Meal Planning
- Regular Physical Activity & Exercise
- Medication Adherence & Administration
- Foot Care Daily Inspection & Prevention
- Sick-Day Management & When to Seek Care
- Recognition of Hypoglycemia & Hyperglycemia Symptoms
- Somogyi Phenomenon vs. Dawn Phenomenon
Relationship to central
Empowers patients to achieve glycemic control and prevent complications
Nursing Assessment & Interventions
Sub concepts
- NANDA Nursing Diagnoses in Diabetes
- Physical Assessment for Complications
- Monitoring Glucose, Vitals, Neuro Status, I&O
- Health Teaching & Patient Advocacy
- Compliance with Antidiabetic Medications
- Prevention of Infection & Wound Care
- Psychosocial Support & Disease Acceptance
Relationship to central
Application of nursing process to diabetes care across all contexts
Concept connections
- Type 1 DMAbsolute Insulin DeficiencyType 1 DM causes autoimmune destruction of pancreatic beta cells, resulting in absolute inability to produce insulin
- Type 1 DMDKAType 1 DM patients are most susceptible to DKA due to complete lack of insulin production
- Type 2 DMInsulin ResistanceType 2 DM is fundamentally characterized by cellular resistance to insulin action combined with progressive beta cell dysfunction
- Type 2 DMHHNSType 2 DM patients are more prone to HHNS because enough residual insulin prevents ketosis but cannot prevent severe hyperglycemia
- HyperglycemiaChronic ComplicationsProlonged hyperglycemia directly causes endothelial damage leading to micro- and macrovascular complications
- Insulin AdministrationHypoglycemia RiskInsulin peak times determine when patients are at highest risk for hypoglycemia; nursing monitoring must align with peak periods
- Regular InsulinIV AdministrationRegular insulin is the only insulin formulation that can be safely administered intravenously; essential for DKA/HHNS management
- NPH InsulinCloudy AppearanceNPH insulin's cloudy appearance indicates suspension of protamine zinc; vial must be gently rolled to redistribute particles before use
- Glargine InsulinNever MixLong-acting glargine must never be mixed with other insulins in the same syringe; always given separately to maintain peakless profile
- MetforminContrast Dye StudiesMetformin must be held around contrast-dye procedures due to risk of lactic acidosis and acute kidney injury
- SulfonylureasHypoglycemiaSulfonylureas stimulate pancreatic insulin release; significant hypoglycemia risk, especially with fasting or alcohol use
- DKAPotassium ShiftIn untreated DKA, acidosis drives potassium out of cells causing falsely high serum levels; insulin and fluids reverse this, causing dangerous hypokalemia
- DKA & HHNSIV Fluids FirstNormal saline 0.9% is the first priority in both acute emergencies to restore intravascular volume and improve perfusion
- RetinopathyTight Glucose ControlMicrovascular damage to retinal capillaries is preventable with HbA1c <7%; regular eye exams are essential screening
- NephropathyACE Inhibitors/ARBsACE-I and ARB medications provide renoprotection in diabetic kidney disease by reducing glomerular pressure independent of glucose control
- NeuropathyFoot Ulcer RiskSensory neuropathy causes loss of protective sensation; combined with poor circulation and infection risk, minor trauma becomes serious ulcers
- Diabetic Foot CareDaily InspectionNeuropathic patients cannot feel pain or pressure from injury; daily visual inspection is the primary prevention strategy for foot complications
- Foot CareNever BarefootPatients with neuropathy lack protective sensation; going barefoot increases trauma risk exponentially, requiring strict prevention education
- Somogyi PhenomenonNocturnal HypoglycemiaSomogyi phenomenon occurs when nighttime hypoglycemia triggers counter-regulatory hormone surge causing morning hyperglycemia
- Dawn PhenomenonEarly Morning HormonesDawn phenomenon is morning hyperglycemia from normal early-morning cortisol and growth hormone surge WITHOUT preceding nocturnal hypoglycemia
- HypoglycemiaRule of 15Rule of 15 (15g carbs, recheck in 15 min, repeat if needed) is the evidence-based protocol for conscious patient treatment
- Unconscious HypoglycemiaIV Dextrose or IM GlucagonUnconscious patients cannot receive oral intake (aspiration risk); must receive IV D50 in hospital or IM/SC glucagon in field settings
- HbA1cTreatment TargetHbA1c reflects average glucose over 2-3 months; diagnostic threshold ≥6.5%, treatment target <7% for most patients
- SMBG (Self-Monitoring Blood Glucose)Patient EmpowermentRegular SMBG allows patients to understand insulin effects, food impacts, and activity relationships; essential for improving self-management
- Cardiovascular DiseaseLeading Cause of DeathMacrovascular complications (CAD, stroke, PVD) account for 85% of diabetes deaths; CV risk reduction is as important as glycemic control
- Rapid-Acting InsulinMeal TimingRapid-acting insulins peak in 30 min-1.5 hours and must be given WITH meals (food ready first) to prevent hypoglycemia
- Intermediate Insulin (NPH)Nocturnal Hypoglycemia RiskNPH peaks at 6-12 hours; evening doses peak overnight, increasing nocturnal hypoglycemia risk requiring 2-3 AM glucose checks
Diagrams
Diabetes Mellitus & Its Complications: Complete Concept Hierarchy
Comprehensive mind map showing all major concept domains in diabetes mellitus management, including pathophysiology, diagnostics, insulin types with their pharmacokinetics, oral agents, acute and chronic complications, and nursing interventions. Color-coded branches organize information by clinical relevance for NLE preparation.
Insulin Pharmacokinetics & Hypoglycemia Risk Timeline
Flow chart illustrating insulin types, their pharmacokinetic profiles, and corresponding times of highest hypoglycemia risk. Critical for understanding when patients are most vulnerable and when nursing monitoring must be most intensive. Peak times are color-coded for easy recall during clinical practice.
DKA vs HHNS: Differential Diagnosis & Management Pathways
Evidence-based management flowchart for acute hyperglycemic emergencies emphasizing the critical potassium monitoring component — a major NLE testing area. Shows parallel management paths, priority sequence (fluids→insulin→potassium), and the pivotal glucose threshold (200-250 mg/dL) for dextrose addition. Includes the reasoning behind each step.
Hypoglycemia Recognition & Emergency Treatment Algorithm
Step-by-step hypoglycemia recognition and treatment protocol using the evidence-based Rule of 15. Separates conscious from unconscious patient pathways, clearly delineates carbohydrate choices, and includes documentation and teaching components essential for preventing recurrence. Emphasizes the critical differentiation between treatment for conscious vs unconscious patients.
Chronic Microvascular Complications: Pathophysiology to Clinical Outcome
State transition diagram showing how uncontrolled hyperglycemia progresses through endothelial damage to develop the three major microvascular complications (retinopathy, nephropathy, neuropathy) and their clinical outcomes. Emphasizes that all are preventable with tight glycemic control, reinforcing the fundamental importance of good glucose management.
Insulin Mixing & Administration: Step-by-Step Safe Procedure
Detailed procedural flowchart for the critical insulin mixing technique, emphasizing the 'clear before cloudy' rule and correct sequence. This is a high-frequency NLE question area. Shows the rationale (preventing contamination of regular insulin with NPH particles) and includes the complete injection procedure from preparation through documentation.
Oral Antidiabetic Agents: Selection & Monitoring Framework
Decision tree for oral antidiabetic agent selection in Type 2 DM, emphasizing first-line (metformin) through add-on therapy options. Includes key monitoring points, hypoglycemia risks, renal considerations, and CV safety — all critical for the NLE and clinical practice. Shows the progression from monotherapy to combination therapy based on A1c goals.
Major Causes of Death in Diabetes: Macrovascular vs Microvascular Impact
Pie chart demonstrating that cardiovascular/macrovascular disease (totaling 85% of diabetes-related deaths) is the leading cause of mortality in diabetic patients, despite intensive microvascular complication prevention efforts. This emphasizes the critical importance of lipid management, blood pressure control, and cardiovascular risk reduction in diabetes care — essential knowledge for comprehensive patient management and NLE success.